Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies

Molecular Immunology

Volumn 73, Issue , 2016, Pages 69-75

  Thomann, Marco ^a   Reckermann, Katharina ^a   Reusch, Dietmar ^a   Prasser, Jessica ^a   Tejada, Max L ^b,c  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b GENENTECH INC   (United States)

^c Gilead Sciences   (United States)

Author keywords

ADCC; Afucosylation; Antibody; CDC; Effector function; Fc glycan; Fucosylation; Galactosylation; IgG1; Natural killer cell

Indexed keywords

CARBOHYDRATE; ENZYME; FC RECEPTOR; GALACTOSE; GLYCAN; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; FUCOSE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING ASSAY; CELL MEDIATED CYTOTOXICITY; DATA BASE; FUCOSYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS; CHEMISTRY; GLYCOSYLATION; IMMUNOLOGY; METABOLISM;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; FUCOSE; GALACTOSE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; RECEPTORS, IGG;

EID: 84962382941     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2016.03.002     Document Type: Article

References (18)

1. Bibeau F., et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 2009, 27:1122-1129.
2. Boyd P.N., Lines A.C., Patel A.K. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 1995, 32:1311-1318.
3. Cartron G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
4. Davies J., et al. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol. Bioeng. 2001, 74:288-294.
5. Ferrara C., et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng. 2006, 93:851-861.
6. Gottschalk P.G., Dunn J.R. Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data. J. Biopharm. Stat. 2005, 15:437-463.
7. Hodoniczky J., Zheng Y.Z., James D.C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 2005, 21:1644-1652.
8. Houde D., Peng Y., Berkowitz S.A., Engen J.R. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol. Cell. Proteomics 2010, 9:1716-1728.
9. Leavy O. Therapeutic antibodies: past, present and future. Nat. Rev. Immunol. 2010, 10:297.
10. ® Technology. Korean J. Hematol. 2011, 46:148-150.
11. Mellor J.D., Brown M.P., Irving H.R., Zalcberg J.R., Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J. Hematol. Oncol. 2013, 6:1.
12. Musolino A., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008, 26:1789-1796.
13. Raju T.S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 2008, 20:471-478.
14. Schnueriger A., et al. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol. Immunol. 2011, 48:1512-1517.
15. Shields R.L., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 277:26733-26740.
16. Shinkawa T., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278:3466-3473.
17. Umana P., Jean-Mairet J., Moudry R., Amstutz H., Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 1999, 17:176-180.
18. Zhou Q., et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol. Bioeng. 2008, 99:652-665.